OncoMed Pharmaceuticals, Inc (OMED) Covered Calls

OncoMed Pharmaceuticals, Inc covered calls OncoMed Pharmaceuticals Inc is a clinical development-stage biotechnology company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells.

You can sell covered calls on OncoMed Pharmaceuticals, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for OMED (prices last updated Mon 4:16 PM ET):

OncoMed Pharmaceuticals, Inc (OMED) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
0.93 -0.05 0.93 0.94 988K - 0.0B
Covered Calls For OncoMed Pharmaceuticals, Inc (OMED)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 21 2.5 0.00 0.94 0.0% 0.0%
Jan 18 2.5 0.00 0.94 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

OncoMed Pharmaceuticals, Inc. is a clinical development-stage biotechnology company that discovers and develops first-in-class protein therapeutics targeting cancer stem cells. The company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. It has six anti-cancer stem cell product candidates in clinical trials: Demcizumab (OMP-21M18), Anti-DLL4/VEGF Bispecific (OMP-305B8), Tarextumab (Anti-Notch2/3, OMP-59R5), Brontictuzumab (Anti-Notch1, OMP-52M5), Vantictumab (Anti-Fzd7, OMP-18R5), RSPO-LGR. Its pipeline also includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways, including the RSPO-LGR pathway, Wnt 3rd Biologic and Wnt Small Molecules. The company was founded by Drs. Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.